[HTML][HTML] Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma
R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
[HTML][HTML] Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
[HTML][HTML] Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report
J Tao, H Yang, Z Hao, C Liang, Y Du, C Zhang, Y Yin… - Medicine, 2022 - journals.lww.com
Interventions: After chemotherapy alone failed, the patient received 6 courses of anlotinib
combined with chemotherapy. The tumor had significantly reduced in size and the recurrent …
combined with chemotherapy. The tumor had significantly reduced in size and the recurrent …
[HTML][HTML] Intestinal haemorrhage and colitis induced by treatment with osimertinib for non-small-cell lung carcinoma: a case report
W Shujun, L Lili, Y Lei, W Feng, Z Hefeng - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Osimertinib is recommended either as the first-line therapy for sensitizing
EGFR-mutations (FLAURA trial) or at progression to first-/second-generation EGFR …
EGFR-mutations (FLAURA trial) or at progression to first-/second-generation EGFR …
Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study
C Cai, Q Shen, J Shao, J Qu… - Technology in Cancer …, 2024 - journals.sagepub.com
There are no standard third-line or beyond treatments for patients with driver mutation-
positive advanced lung adenocarcinoma (LUAD). Anlotinib was approved as a third-line …
positive advanced lung adenocarcinoma (LUAD). Anlotinib was approved as a third-line …
[HTML][HTML] Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
Y Chen, N Jiang, X Liang, N Chen… - Oncology …, 2023 - spandidos-publications.com
The current treatment options for epidermal growth factor receptor (EGFR) mutation‑positive
lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although …
lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although …
Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
M Wang, J Zhao, T Chen, X Hu, L Wang, Y Shi… - Thoracic …, 2023 - Wiley Online Library
Objective To retrospectively analyze the efficacy and safety of osimertinib combined with
anlotinib in the treatment of advanced non‐small‐cell lung cancer (NSCLC) after drug …
anlotinib in the treatment of advanced non‐small‐cell lung cancer (NSCLC) after drug …
The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression …
Y Zhang, C Wang, J Zhao, M Wang - Thoracic Cancer, 2024 - Wiley Online Library
Background Epidermal growth factor receptor (EGFR) mutations are key drivers in a
significant portion of non‐small‐cell lung cancer (NSCLC) patients. While third‐generation …
significant portion of non‐small‐cell lung cancer (NSCLC) patients. While third‐generation …
[HTML][HTML] 抗血管生成药物联合EGFR-TKI 治疗EGFR 突变晚期非小细胞肺癌的研究进展
李博文， 薛剑超， 王亚东， 黄志诚， 梁乃新… - Chinese Journal of …, 2022 - ncbi.nlm.nih.gov
肺癌是最常见、 致死率最高的肿瘤性疾病之一， 使用表皮生长因子受体酪氨酸激酶抑制剂（
epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI） 已经成为EGFR …
epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI） 已经成为EGFR …
[HTML][HTML] The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
H Xiang, D Danna, C Xuefei, J Zhao, G Jin - Anti-Cancer Drugs, 2024 - journals.lww.com
Acquired resistance is unavoidable with the approval of third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for first-line therapy of advanced non …
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for first-line therapy of advanced non …